Michael Burczynski | Executive Director, Head Of Integrated Clinical Biomarker Technologies
Bristol-Myers Squibb

Michael Burczynski, Executive Director, Head Of Integrated Clinical Biomarker Technologies, Bristol-Myers Squibb

Dr. Michael E. (Ted) Burczynski is a Senior Director and Head of Translational Biomarker Research at Teva Pharmaceuticals. He received a PhD in pharmacology from the University of Pennsylvania School of Medicine and conducted his postdoctoral work in toxicogenomics at Johnson and Johnson’s R.W. Johnson Pharmaceutical Research Institute.  He has previously led translational research groups and biomarker laboratories at Wyeth, Roche and BMS. He is currently an adjunct professor in the Department of Systems Pharmacology at the University of Pennsylvania.  He has edited two textbooks and published over a hundred abstracts, articles, reviews and book chapters in the fields of genomics and biomedical research.
 
In his spare time he is a novelist and writes under the pen name Michael Ransom. His debut novel THE RIPPER GENE was published by Tor-Forge (Macmillan) in 2015. THE RIPPER GENE won multiple Silver Falchion literary awards for “Best Horror Novel” and “Best Serial Killer Mystery” in 2016 (www.michaelransombooks.com).

Appearances:



BioData West: Day 1 @ 12:20

INTERACTIVE E ROUNDTABLES

        1) Integrating EMR - Integration of electronic medical records with a biomedical knowledge network to predict medical outcomes
Chair: Sergio Baranzini, Professor UCSF

        2)  Collaboration - How to enable researchers to use data and collaborate easier?
Chair: Christopher Riley, Research Administration Manager, The Institute for Precision Cardiovascular Medicine

       3) Quantum Computing -  Where are we and what we are doing?
Chair: Handol Kim, General Manager, Quadrant Machine Learning Business Unit, D-Wave Systems, Inc

       4) CLSA California - Partnering and driving a hot bed of translational medicine in California
Chair: Sara Radcliff, President and Chief Executive Officer, California Life Sciences Association

       5) Electronic Consent - How to develop an electronic e-trial strategy effectively?
Chair: Megan Doerr, Principal Scientist, Sage Bionetworks
Sarah Meeder, Research Compliance Specialist, CUNY

       6) Personal Genetic Testing - What are the impacts and implications?
Chair: Westyn Branch-Elliman, Instructor in Medicine, Harvard Medical School
      
       7) Drug Discovery - Expediting the drug development through genomics, structural and cultural changes 
Chair: Nadeem Sarwar, President, AiM Institute, Eisai
          
       8) Big Data and the CNS - using big data datasets and approaches in the development of medicines for CNS indications including NDDs and pain/migraine disorders
Chair: Michael Burczynski, Senior Director and Head of Translational Biomarker Research, Early Stage Development, Teva

       9) Stem Cells & Rare Disseises - How to develop an infrastructure in which researchers can be connected with patients and tools to develop therapies

     10) Text mining and Image Recognition - Developing new tools
Chair: Karim Galil, CEO, Mendel Health

     11) Scientific Software- Enabling research at Verily
Chair: Mauricio Carneiro, Head of Scientific Software, Verily (Google Life Sciences)

     12) Standards in Genetic Testing – Setting the benchmark in quality data sets
Chair: Robert Burton, Founder and CEO, Center for Genomic Interpretation
 

Big Data and the CNS - using big data datasets and approaches in the development of medicines for CNS indications including NDDs and pain/migraine disorders

back to speakers